SB 202190 is a highly selective p38 MAPK inhibitor. In a rabbit model, treatment with SB 202190 after filtering glaucoma surgery improved bleb characteristics and intraocular pressure. In a chronic hypoperfusion rat model of vascular dementia, treatment with SB 202190 reduced apoptosis of hippocampal neurons and rescued spatial learning and memory deficits.
| Cas No. | 152121-30-7 |
|---|---|
| Purity | ≥99% |
| Formula | C20H14FN3O |
| Formula Wt. | 331.35 |
| Chemical Name | 4-[4-(4-Fluorophenyl)-5-(4-pyridinyl)-1H-imidazol-2-yl]phenol |
| IUPAC Name | 4-[4-(4-fluorophenyl)-5-pyridin-4-yl-1,3-dihydroimidazol-2-ylidene]cyclohexa-2,5-dien-1-one |
| Synonym | SB202190; SB-202190; FHPI; UNII-PVX798P8GI ; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole |
| Solubility | Soluble in DMSO to 100 mM, 20mg/mL in ethanol, 2mg/mL in Ethyl acetate |
| Appearance | Yellow Powder |
| MSDS | |
|---|---|
| Info Sheet |
Nassar K, Tura A, Luke J, et al. A p38 MAPK inhibitor improves outcome after glaucoma filtration surgery. J Glaucoma. 2015 Feb;24(2):165-178. PMID: 25493622.
Yang S, Zhou G, Liu H, et al. Protective effects of p38 MAPK inhibitor SB202190 against hippocampal apoptosis and spatial learning and memory deficits in a rat model of vascular dementia. Biomed Red Int. 2013;2013:215798. PMID: 24455679.
